Polar Asset Management Partners Inc. Takes $7.74 Million Position in Kenvue Inc. $KVUE

Key Points

• Polar Asset Management acquired 405,241 Kenvue shares worth approximately $7.74 million during the second quarter. Institutional investors collectively own 97.64% of the company.
• Kenvue’s latest quarterly results slightly missed expectations, with EPS of $0.31 versus $0.32 expected and revenue of $3.96 billion versus $3.97 billion forecast, though revenue rose 3% year over year.
• The company’s $0.21 quarterly dividend equates to an annualized yield of about 4.3%. Analysts remain cautious, with Kenvue carrying a consensus “Hold” rating and an average price target of $19.27.

Polar Asset Management Partners Inc. purchased a new stake in Kenvue Inc. (NYSE:KVUE - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 405,241 shares of the company's stock, valued at approximately $7,744,000.

Other hedge funds have also bought and sold shares of the company. Physician Wealth Advisors Inc. grew its position in shares of Kenvue by 67.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company's stock worth $26,000 after purchasing an additional 618 shares in the last quarter. Elyxium Wealth LLC acquired a new stake in shares of Kenvue in the fourth quarter valued at approximately $26,000. Johnson Financial Group Inc. bought a new stake in shares of Kenvue in the second quarter valued at approximately $26,000. MV Capital Management Inc. bought a new stake in shares of Kenvue in the fourth quarter valued at approximately $28,000. Finally, CoreCap Advisors LLC grew its position in Kenvue by 64.9% during the second quarter. CoreCap Advisors LLC now owns 1,502 shares of the company's stock worth $29,000 after buying an additional 591 shares in the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Down 0.4%

NYSE KVUE opened at $19.34 on Wednesday. The business has a fifty day moving average price of $19.10 and a two-hundred day moving average price of $18.22. The stock has a market capitalization of $37.16 billion, a PE ratio of 22.24, a PEG ratio of 1.39 and a beta of 0.47. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $21.40. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.01 and a quick ratio of 0.71.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.01). Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The business had revenue of $3.96 billion during the quarter, compared to the consensus estimate of $3.97 billion. During the same quarter in the previous year, the business posted $0.29 EPS. The company's revenue for the quarter was up 3.0% on a year-over-year basis. Equities analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, August 26th. Shareholders of record on Wednesday, August 12th will be paid a dividend of $0.21 per share. The ex-dividend date of this dividend is Wednesday, August 12th. This is a positive change from Kenvue's previous quarterly dividend of $0.21. This represents a $0.84 annualized dividend and a yield of 4.3%. Kenvue's payout ratio is presently 96.55%.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on KVUE shares. Wall Street Zen lowered Kenvue from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. Barclays increased their target price on Kenvue from $18.00 to $19.00 and gave the stock an "equal weight" rating in a report on Tuesday, July 21st. UBS Group dropped their price target on Kenvue from $20.00 to $19.00 and set a "neutral" rating for the company in a research note on Tuesday, August 11th. Weiss Ratings raised shares of Kenvue from a "hold (c-)" rating to a "hold (c)" rating in a research report on Monday, June 15th. Finally, Zacks Research downgraded shares of Kenvue from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 7th. Three investment analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $19.27.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source